Scaling up from µg to gram: CEO Hycult Biotech acquires Biocult

Uden, The Netherlands, June 2019 – Mr. Ronald de Niet is pleased to announce the acquisition of Biocult. Biocult is an internationally operating company with 20 years’ experience in upscaling of monoclonal antibodies. Since Biocult was established in 1992, they have processed over 200 different cell lines including hybridomas, transfectomas. BHK, CHO and PerC6 cells.

Dr. van de Griend (CEO and founder of Biocult) with Mr. de Niet (CEO Hycult Biotech) a few moments after signing the contract.

Hycult Biotech was founded in 1994 by Mr. Wim de Niet, father of current CEO and owner Mr. Ronald de Niet. Hycult Biotech is proud with what is achieved in these 25 years: a broad range of high quality products, an own subsidiary in the USA, a fully updated ISO13485:2016 quality system and GMP facilities. Mr. Ronald de Niet: “Being an independent privately owned company we strive to continue the next 25 years with making more tools for research in innate immunity and expanding and sharing our knowledge in projects and to scientists all around the world. These 25 years could not have been possible without our customers and collaborations.”